{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:19:49Z","timestamp":1776867589944,"version":"3.51.2"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005765","name":"Universidade de Lisboa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005765","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Aspirin use among patients with diabetes in primary prevention is still a matter of debate. We aimed to evaluate the potential cardiovascular risk benefit of aspirin in primary prevention, using data from a contemporary cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective analysis of the VITAL cohort with\u2009&gt;\u200920,000 individuals at primary prevention who were followed for a median of 5.3\u00a0years. The population was evaluated according to the baseline diabetes status, and then aspirin use was evaluated among diabetic patients. Cox regression models were used to estimate the risks of mortality and cardiovascular outcomes. The estimates were reported using adjusted hazard ratio (HR) and 95% confidence intervals (95%CI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Diabetic patients (<jats:italic>n<\/jats:italic>\u2009=\u20093549; 13.7%) showed to increase the risk of all-cause mortality (HR 1.61, 95%CI 1.33\u20131.94), and major adverse cardiovascular events (MACE) (HR 1.36 95%CI 1.11\u20131.68) than non-diabetic population. Diabetic patients taking aspirin were older, more frequently man, hypertensive, current users of statins, and current smokers compared with diabetic patients who did not use aspirin at baseline. There was no difference between diabetic aspirin users and non-users regarding all-cause mortality (HR 0.80, 95%CI 0.59, 1.10), MACE (HR 0.92, 95%CI 0.64, 1.33), coronary heart disease (HR 0.98, 95%CI 0.67, 1.43), or stroke (HR 0.87, 95%CI 0.48, 1.58).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The VITAL data confirmed diabetes as an important risk factor for cardiovascular events in a contemporary cohort but did not show cardiovascular benefits of aspirin in primary prevention among people with diabetes who were shown to be at higher risk of cardiovascular events.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-022-02001-3","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T06:03:13Z","timestamp":1674021793000},"page":"1423-1428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort"],"prefix":"10.1007","volume":"46","author":[{"given":"D.","family":"Caldeira","sequence":"first","affiliation":[]},{"given":"M.","family":"Alves","sequence":"additional","affiliation":[]},{"given":"J. J.","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"F. J.","family":"Pinto","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"issue":"9438","key":"2001_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, \u00d4unpuu S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438):937\u2013952. https:\/\/doi.org\/10.1016\/S0140-6736(04)17018-9","journal-title":"Lancet"},{"issue":"7533","key":"2001_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/bmj.38678.389583.7C","volume":"332","author":"R Huxley","year":"2006","unstructured":"Huxley R, Barzi F, Woodward M (2006) Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332(7533):73\u201378. https:\/\/doi.org\/10.1136\/bmj.38678.389583.7C","journal-title":"BMJ"},{"issue":"10046","key":"2001_CR3","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0140-6736(16)30506-2","volume":"388","author":"MJ O\u2019Donnell","year":"2016","unstructured":"O\u2019Donnell MJ, Chin SL, Rangarajan S et al (2016) Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 388(10046):761\u2013775. https:\/\/doi.org\/10.1016\/S0140-6736(16)30506-2","journal-title":"Lancet"},{"issue":"19","key":"2001_CR4","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","volume":"241","author":"WB Kannel","year":"1979","unstructured":"Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease the framingham study. J American Med Associat. 241(19):2035\u20132038","journal-title":"J American Med Associat."},{"issue":"16","key":"2001_CR5","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","author":"L Bowman","year":"2018","unstructured":"ASCEND Study Collaborative Group, Bowman L, Mafham M et al (2018) Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 379(16):1529\u20131539","journal-title":"N Engl J Med"},{"issue":"34","key":"2001_CR6","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM et al (2021) 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42(34):3227\u20133337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484","journal-title":"Eur Heart J"},{"issue":"1","key":"2001_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/AJE\/KWH010","volume":"159","author":"E White","year":"2004","unstructured":"White E, Patterson RE, Kristal AR et al (2004) VITamins and lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol 159(1):83\u201393. https:\/\/doi.org\/10.1093\/AJE\/KWH010","journal-title":"Am J Epidemiol"},{"issue":"1","key":"2001_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/J.CCT.2011.09.009","volume":"33","author":"JAE Manson","year":"2012","unstructured":"Manson JAE, Bassuk SS, Lee IM et al (2012) The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 33(1):159\u2013171. https:\/\/doi.org\/10.1016\/J.CCT.2011.09.009","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"2001_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMOA1809944","volume":"380","author":"JE Manson","year":"2019","unstructured":"Manson JE, Cook NR, Lee IM et al (2019) Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med 380(1):33\u201344. https:\/\/doi.org\/10.1056\/NEJMOA1809944","journal-title":"N Engl J Med"},{"key":"2001_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.720113","author":"Y Chen","year":"2021","unstructured":"Chen Y, Yin C, Li Q et al (2021) Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease. Frontier Cardiovas Med. https:\/\/doi.org\/10.3389\/fcvm.2021.720113","journal-title":"Frontier Cardiovas Med."},{"issue":"3","key":"2001_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/J.PCD.2019.11.004","volume":"14","author":"D Caldeira","year":"2020","unstructured":"Caldeira D, Alves M, David C, Costa J, Ferreira JJ, Pinto FJ (2020) Aspirin in the primary prevention of cardiovascular disease on diabetic patients: Systematic review and meta-analysis. Prim Care Diabetes 14(3):213\u2013221. https:\/\/doi.org\/10.1016\/J.PCD.2019.11.004","journal-title":"Prim Care Diabetes"},{"key":"2001_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319825510","author":"SU Khan","year":"2019","unstructured":"Khan SU, Ul Z, Asad A et al (2019) Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus\u202f: An updated systematic review and meta-analysis. Published online. https:\/\/doi.org\/10.1177\/2047487319825510","journal-title":"Published online"},{"issue":"13","key":"2001_CR13","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1161\/CIRCULATIONAHA.117.028321","volume":"136","author":"J Sundstr\u00f6m","year":"2017","unstructured":"Sundstr\u00f6m J, Hedberg J, Thuresson M, Aarskog P, Johannesen KM, Oldgren J (2017) Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide. Popul-Based Cohort Study Circulat 136(13):1183\u20131192. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.028321","journal-title":"Popul-Based Cohort Study Circulat"},{"key":"2001_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/J.CCT.2015.12.022","volume":"47","author":"SS Bassuk","year":"2016","unstructured":"Bassuk SS, Manson JAE, Lee IM et al (2016) Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL). Contemp Clin Trials 47:235\u2013243. https:\/\/doi.org\/10.1016\/J.CCT.2015.12.022","journal-title":"Contemp Clin Trials"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-02001-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-022-02001-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-02001-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T09:22:26Z","timestamp":1686561746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-022-02001-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":14,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["2001"],"URL":"https:\/\/doi.org\/10.1007\/s40618-022-02001-3","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"5 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DC has participated in educational meetings and\/or attended a conferences or symposia (including travel, accommodation and\/or hospitality) with Bial, Bristol-Myers Squibb, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Merck Serono, Ferrer, Pfizer, Novartis and Roche. JJF is a consultant for Ipsen, GlaxoSmithKline, Novartis, Teva, Lundbeck, Solvay, Abbott, BIAL, Merck Serono, and Merz and received grants from GlaxoSmithKline, Grunenthal, Teva, and Funda\u00e7\u00e3o MSD. FJP had consultant and speaker fees with Astra Zeneca, Bayer, BMS, Boehringer Ingelheim and Daiichi Sankyo. The remaining authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This was a retrospective evaluation of the VITAL trial using data provided by the Project Data Sphere (). Detailed methodology and main results of the trial have been published elsewhere. The dataset used is de-identified and public according to request to PDS. This project complies with the principles of the Declaration of Helsinki as revised in 2008.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals and informed consent"}}]}}